S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
A One Stop Shop for Everything Futures Trading (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
A One Stop Shop for Everything Futures Trading (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
A One Stop Shop for Everything Futures Trading (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
A One Stop Shop for Everything Futures Trading (Ad)pixel
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
A One Stop Shop for Everything Futures Trading (Ad)pixel
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
A One Stop Shop for Everything Futures Trading (Ad)pixel
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
OTCMKTS:SPHRY

Starpharma - SPHRY Stock Forecast, Price & News

$3.80
0.00 (0.00%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.80
$3.80
50-Day Range
$3.76
$5.65
52-Week Range
$3.76
$9.50
Volume
300 shs
Average Volume
2,484 shs
Market Capitalization
$155.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SPHRY stock logo

About Starpharma (OTCMKTS:SPHRY) Stock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Receive SPHRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter.

SPHRY Stock News Headlines

Starpharma signs new DEP® agreement with MSD
Starpharma Holdings Ltd. ADR (SPHRY)
Viraleze registered for sale in Covid-ravaged India
See More Headlines
Receive SPHRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Starpharma and its competitors with MarketBeat's FREE daily newsletter.

SPHRY Company Calendar

Today
10/02/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SPHRY
CIK
N/A
Employees
50
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.61 million
Book Value
$1.15 per share

Miscellaneous

Free Float
N/A
Market Cap
$155.19 million
Optionable
Not Optionable
Beta
1.55

Key Executives

  • Dr. Jacinth K. Fairley B.Sc. (Age 59)
    B.V.Sc.(Hons), MBA, GAICD, CEO, MD & Exec. Director
    Comp: $520.77k
  • Mr. Nigel J. Baade B.Com
    Grad. Dip., CPA, CFO & Company Sec.













SPHRY Stock - Frequently Asked Questions

How have SPHRY shares performed in 2022?

Starpharma's stock was trading at $9.50 at the beginning of 2022. Since then, SPHRY shares have decreased by 60.0% and is now trading at $3.80.
View the best growth stocks for 2022 here
.

What is Starpharma's stock symbol?

Starpharma trades on the OTCMKTS under the ticker symbol "SPHRY."

How do I buy shares of Starpharma?

Shares of SPHRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Starpharma's stock price today?

One share of SPHRY stock can currently be purchased for approximately $3.80.

How much money does Starpharma make?

Starpharma (OTCMKTS:SPHRY) has a market capitalization of $155.19 million and generates $1.61 million in revenue each year.

How can I contact Starpharma?

Starpharma's mailing address is 4-6 Southampton Crescent, Abbotsford C3, 3072. The official website for the company is www.starpharma.com. The company can be reached via phone at (138) 532-2700, via email at investor.relations@starpharma.com, or via fax at 61-3-9510-5955.

This page (OTCMKTS:SPHRY) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.